ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation

This study is currently recruiting participants.
Verified by Alberta Cancer Board, April 2007

Sponsored by: Alberta Cancer Board
Information provided by: Alberta Cancer Board
ClinicalTrials.gov Identifier: NCT00126854
  Purpose

The purpose of this study is to establish the correct scanning parameters for obtaining good quality 3 Tesla (3T) magnetic resonance spectroscopy images (MRSI) of the prostate gland before and after brachytherapy implantation for prostate cancer. Three Tesla MRSI may be a valuable additional diagnostic and follow-up investigation for prostate cancer patients.


Condition Intervention
Prostatic Neoplasm
Procedure: Magnetic Resonance Spectroscopy Imaging

MedlinePlus related topics:   Cancer    Prostate Cancer   

ChemIDplus related topics:   Iodine    Cadexomer iodine   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:   High Field (3 Tesla) Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Permanent Iodine 125 Brachytherapy Implantation

Further study details as provided by Alberta Cancer Board:

Primary Outcome Measures:
  • pilot study meant to establish scanning parameters on 3T MRSI

Secondary Outcome Measures:
  • safety/toxicity

Estimated Enrollment:   10
Study Start Date:   October 2005
Estimated Study Completion Date:   November 2007

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Suitable candidate for prostate brachytherapy to treat prostate cancer
  • Patient signs a study consent form

Exclusion Criteria:

  • Have received other radiotherapy for prostate cancer or hormone treatments
  • Has contraindication to MRSI scanning
  • Does not sign study consent form
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00126854

Contacts
Contact: Don Yee, MD     780-432-8749     donyee@cancerboard.ab.ca    

Locations
Canada, Alberta
Cross Cancer Institute     Recruiting
      Edmonton, Alberta, Canada, T6G 1Z2
      Contact: Paula Langenhoff     780-432-8909     paulalan@cancerboard.ab.ca    
      Principal Investigator: Don Yee, MD            

Sponsors and Collaborators
Alberta Cancer Board

Investigators
Principal Investigator:     Don Yee, MD     Alberta Cancer Board    
  More Information

Study ID Numbers:   NA-15-0003
First Received:   August 3, 2005
Last Updated:   April 10, 2007
ClinicalTrials.gov Identifier:   NCT00126854
Health Authority:   Canada: Health Canada

Keywords provided by Alberta Cancer Board:
brachytherapy  
magnetic resonance spectroscopy  

Study placed in the following topic categories:
Prostatic Diseases
Genital Neoplasms, Male
Iodine
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on August 28, 2008




Links to all studies - primarily for crawlers